RESUMO
Recently the coronavirus disease (COVID-19) outbreak has been declared a pandemic. Despite its aggressive extension and significant morbidity and mortality, risk factors are poorly characterized outside China. We designed a registry, HOPE COVID-19 (NCT04334291), assessing data of 1021 patients discharged (dead or alive) after COVID-19, from 23 hospitals in 4 countries, between 8 February and 1 April. The primary end-point was all-cause mortality aiming to produce a mortality risk score calculator. The median age was 68 years (IQR 52-79), and 59.5% were male. Most frequent comorbidities were hypertension (46.8%) and dyslipidemia (35.8%). A relevant heart or lung disease were depicted in 20%. And renal, neurological, or oncological disease, respectively, were detected in nearly 10%. Most common symptoms were fever, cough, and dyspnea at admission. 311 patients died and 710 were discharged alive. In the death-multivariate analysis, raised as most relevant: age, hypertension, obesity, renal insufficiency, any immunosuppressive disease, 02 saturation < 92% and an elevated C reactive protein (AUC = 0.87; Hosmer-Lemeshow test, p > 0.999; bootstrap-optimist: 0.0018). We provide a simple clinical score to estimate probability of death, dividing patients in four grades (I-IV) of increasing probability. Hydroxychloroquine (79.2%) and antivirals (67.6%) were the specific drugs most commonly used. After a propensity score adjustment, the results suggested a slight improvement in mortality rates (adjusted-ORhydroxychloroquine 0.88; 95% CI 0.81-0.91, p = 0.005; adjusted-ORantiviral 0.94; 95% CI 0.87-1.01; p = 0.115). COVID-19 produces important mortality, mostly in patients with comorbidities with respiratory symptoms. Hydroxychloroquine could be associated with survival benefit, but this data need to be confirmed with further trials. Trial Registration: NCT04334291/EUPAS34399.
Assuntos
COVID-19/mortalidade , Idoso , COVID-19/complicações , COVID-19/terapia , Feminino , Hospitalização , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Pontuação de Propensão , Sistema de Registros , Medição de Risco , Fatores de Risco , Espanha , Taxa de SobrevidaRESUMO
La EEPC practicada en el hombre de manera rutinaria, nació en 1967, simultáneamente en París (Coumel) y en Amsterdam (Durrer). Poco a poco la electrofisiología diagnóstica cedió el paso a la electrofisiología terapéutica con la ARF en 1987, hasta cambiar sus objetivos y establecer su real utilidad al estratificar riesgo, indicar pronóstico (incluidas las canalopatías), predecir muerte súbita (MS) cardíaca y acercarse al riesgo de arritmias ventriculares malignas (AVM)(AU)
